A key function of our immune system is to detect and eliminate foreign pathogens such as bacteria and viruses. Immune cells like T cells do this by distinguishing between different types of proteins within cells, which allows ...
Aug 6, 2023
0
43
Factors associated with improved survival in metastatic uveal melanoma include female sex and use of anti‐cytotoxic T lymphocyte-associated antigen (CTLA)‐4 and anti‐programmed cell death protein 1 (PD-1) therapies, ...
Jul 13, 2023
0
2
Scientists at the UCLA Jonsson Comprehensive Cancer Center have identified potential new biomarkers that could indicate how someone diagnosed with metastatic melanoma will respond to immunotherapy treatment.
Jun 26, 2023
0
47
Even as pancreatic cancer treatments improve, only about 9% of patients survive past five years. Researchers have searched unsuccessfully to find genetic differences that explain why some patients survive long term and some ...
Apr 3, 2023
0
72
A novel approach to administer intrathecal (IT) immunotherapy (directly into the spinal fluid) and intravenous (IV) immunotherapy was safe and improved survival in a subset of patients with leptomeningeal disease (LMD) from ...
Mar 30, 2023
0
21
For the first time, a research team has identified and analyzed the steps by which immune cells "see" and respond to cancer cells, providing insights into reasons some treatments may be effective for certain patients but ...
Mar 8, 2023
0
55
A new research paper titled "Impact of COVID-19 on the management of patients with metastatic melanoma" has been published in Oncotarget.
Jan 11, 2023
0
39
A new multidrug treatment for patients with stage IV melanoma has proven effective after a three-year clinical trial at the University of Colorado Cancer Center.
Dec 16, 2022
0
29
A patient's own immune cells, multiplied into an army of billions of immune cells in a lab, can be used as a living medicine against metastatic melanoma, an aggressive form of skin cancer, as the TIL trial has shown. The ...
Dec 8, 2022
0
3
A clinical trial led by clinicians at Georgetown Lombardi Comprehensive Cancer Center showed a remarkable 20 percent advantage in the two-year overall survival rate for people with advanced melanoma who first received immunotherapy ...
Sep 27, 2022
0
21
